A PYMNTS Company

Sun Pharma to Pay $200 Million to Settle US Price-Fixing Allegations

By  |  July 24, 2025

Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to pay $200 million to settle antitrust claims in the United States, according to Bloomberg. The case, brought in Pennsylvania’s Eastern District Court, centers on allegations that Sun Pharma and other companies colluded to fix prices of generic medications.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The settlement was reached through Sun’s U.S. subsidiaries — Sun Pharmaceutical Industries Inc. and Taro Pharmaceuticals USA Inc. — which will compensate consumers who were allegedly overcharged for 18 generic drugs. Per Bloomberg, this agreement resolves all claims against the two companies without them admitting to any wrongdoing. The final terms are still subject to court approval.

    According to a filing with Indian stock exchanges, Sun Pharma noted that the $200 million settlement amount could be adjusted downward if a substantial portion of the class members choose to opt out of the lawsuit.

    Read more: Monopsony Power in the Hospital Labor Market

    Sun Pharma, India’s largest drugmaker, generated $6.1 billion in revenue for fiscal year 2025, with about one-third of its sales stemming from the U.S. market. Among its best-selling generics in the United States is Revlimid, a treatment for multiple myeloma, a cancer affecting plasma cells.

    The case is part of a broader series of potential class action lawsuits involving several pharmaceutical manufacturers accused of inflating prices on widely-used generic drugs. The U.S. government and private consumers have increasingly targeted these companies in recent years amid concerns over rising healthcare costs.

    In addition to the antitrust settlement, Sun Pharma also resolved a separate patent dispute this month with Incyte Corp. over the hair loss treatment Leqselvi. As part of that agreement, Sun secured licensing rights to market the drug in the U.S., though financial terms were not disclosed, according to Bloomberg.

    Source: Bloomberg